ReviewFrontiers in neurology2020
Intracranial Hemorrhage After Reperfusion Therapies in Acute Ischemic Stroke Patients.
Review in Frontiers in neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Efficacy and safety of Tirofiban following intravenous thrombolysis: a systematic review and meta-analysis of randomized controlled trials.BMC neurology · 2026Pooled it
- Impact of prior antiplatelet therapy on safety and efficacy of alteplase in acute ischemic stroke: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Pooled it
- Risk prediction models for intracranial hemorrhage in acute ischemic stroke patients receiving intravenous alteplase treatment: a systematic review.Frontiers in neurology · 2023Pooled it
- Effect of IV Thrombolysis With Alteplase in Patients With Vessel Occlusion in the WAKE-UP Trial.Neurology · 2025Trial
- Symptomatic Intracranial Hemorrhage After Endovascular Stroke Treatment: External Validation of Prediction Models.Stroke · 2023Trial
- caADAMTS13 reduces neutrophil-mediated vascular inflammation without exacerbating bleeding in experimental intracerebral haemorrhage.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2026Article
- Clinical and Demographic Factors Associated With Hemorrhagic Transformation Subtypes After Endovascular Thrombectomy for Acute Ischemic Stroke.Stroke (Hoboken, N.J.) · 2026Article
- Von Willebrand factor A1 blockade prevents platelet-mediated sustained occlusion for the treatment of arterial thrombosis.Communications biology · 2026Article
- Hemorrhagic transformation during inter-hospital transfer for thrombectomy: Incidence, associated factors, and relationship with outcome.European stroke journal · 2026Article
- Hemorrhagic transformation after endovascular treatment: Baseline infarct volume is a better predictor than infarct growth rate.European stroke journal · 2026Article
- Machine Learning-Based Risk Stratification for Symptomatic Intracranial Hemorrhage and 3-Month Prognosis following Intravenous Thrombolysis.Cerebrovascular diseases extra · 2026Article
- High neutrophil-to-albumin ratio signals severe prognosis in LVO stroke-data from an EICU cohort.Frontiers in medicine · 2026Article
- Direct thrombectomy versus bridging alteplase medicine in anterior circulation stroke following endovascular therapy: a multi-center cohort study.European journal of medical research · 2025Article
- Successful invasive treatment of stroke in a patient with a left ventricle assist device - case report.Postepy psychiatrii neurologii · 2025Article
- Cardiovascular Risk Factors Involved in Hemorrhagic Transformation After Intravenous Thrombolytic Therapy in Patients with Acute Ischemic Stroke.International journal of molecular sciences · 2025Review
- Optimal Timing of Post-Alteplase Brain Computed Tomography: Routine Twenty-Four-Hour Versus Extended Forty-Eight-Hour for Detecting Asymptomatic Intracranial Hemorrhage.Journal of clinical medicine research · 2025Article
- Evaluating the Safety and Efficacy of Intravenous Thrombolysis in Acute Ischemic Stroke Patients Without Perfusion Deficit: A Retrospective Analysis.Brain sciences · 2025Article
- Fusion Learning from Non-contrast CT Scans for the Detection of Hemorrhagic Transformation in Stroke Patients.Journal of imaging informatics in medicine · 2025Article
- The Brush Sign Is Associated with a More Severe Oxygen Metabolic Impairment of the Ischemic Penumbra: An MRI-Based Study in Patients with Acute Stroke.AJNR. American journal of neuroradiology · 2025Observational
- Hemorrhagic transformation after endovascular treatment: Baseline infarct volume is a better predictor than infarct growth rate.European stroke journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reperfusion therapies are the mainstay of acute ischemic stroke (AIS) treatments and overall improve functional outcome. Among the established complications of intravenous (IV) tissue-type plasminogen activator (tPA), intracranial hemorrhage (ICH) is by far the most feared and has been extensively described by seminal works over the last two decades. Indeed, IV tPA is associated with increased odds of any ICH and symptomatic ICH responsible for increased mortality rate during the first week after an AIS. Despite these results, IV tPA has been found beneficial in several pioneering randomized trials and improves functional outcome at 3 months. Endovascular therapy (EVT) combined with IV tPA for AIS patients consecutive to an anterior circulation large-vessel occlusion does not increase ICH occurrence. Of note, EVT following IV tPA leads to significantly higher rates of early reperfusion than with IV tPA alone, with no difference in ICH, which challenges the paradigm of reperfusion as a major prognostic factor for ICH complications. However, several blood biomarkers (glycemia, platelet and neutrophil count), clinical factors (age, AIS severity, blood pressure management, diabetes mellitus), and neuroradiological factors (cerebral microbleeds, infarct size) have been identified as risk factors for ICH after reperfusion therapy. In the years to come, the ultimate goal will be to further improve either reperfusion rates and functional outcome, while reducing hemorrhagic complications. To this end, various approaches being investigated are discussed in this review, such as blood-pressure control after reperfusion or the use of new antiplatelet agents as an adjunct to IV tPA and exhibit reduced hemorrhagic potential during the early phase of AIS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.